إسرائيل -
الإنجليزية -
Ministry of Health
entyvio i.v.
takeda israel ltd - vedolizumab - powder for concentrate for solution for infusion - vedolizumab 300 mg/vial - vedolizumab - ulcerative colitis:entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (tnfα) antagonist.crohn’s disease:entyvio is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (tnfα) antagonist.
إسرائيل -
الإنجليزية -
Ministry of Health
ninlaro 2.3 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 2.3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
إسرائيل -
الإنجليزية -
Ministry of Health
ninlaro 2.3 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 2.3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
إسرائيل -
الإنجليزية -
Ministry of Health
ninlaro 3 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
إسرائيل -
الإنجليزية -
Ministry of Health
ninlaro 3 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
إسرائيل -
الإنجليزية -
Ministry of Health
ninlaro 4 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 4 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
إسرائيل -
الإنجليزية -
Ministry of Health
ninlaro 4 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 4 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
إسرائيل -
الإنجليزية -
Ministry of Health
feiba 1000u
takeda israel ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for injection/infusion - factor viii inhibitor bypassing fraction 1000 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors .control of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available.
إسرائيل -
الإنجليزية -
Ministry of Health
mepact
takeda israel ltd - mifamurtide - powder for concentrate for dispersion for infusion - mifamurtide 4 mg/vial - mifamurtide - mepact is indicated in children, adolescents and young adults for the treatment of high grade resectable non metastatic osteosarcoma after macroscopically complete surgical resection. it is used in combination with post operative multi-agent chemotherapy. safety and efficacy have been assessed in studies of patients 2 to 30 years of age at initial diagnosis.
إسرائيل -
الإنجليزية -
Ministry of Health
condylox
takeda israel ltd - podophyllotoxin - solution - podophyllotoxin 5 mg/ml - podophyllotoxin - podophyllotoxin - treatment of external genital warts (condyloma acuminatum).